I. The Documented Problem

Microplastic contamination of human tissue is genuinely documented by independent, peer-reviewed research: particles have been confirmed in blood (Leslie et al., 2022, Environment International), lung tissue (Amato-Lourenco et al., 2021, THORAX), liver tissue (Horvatits et al., 2022, eBioMedicine), placenta (Ragusa et al., 2021, Environment International), breast milk (Ragusa et al., 2022, Polymers), testicular tissue (Zhao et al., 2023, Science of the Total Environment), and brain tissue (Araujo et al., 2023). A 2024 study published in the New England Journal of Medicine found that patients with microplastics detected in carotid artery plaques had a significantly elevated risk of heart attack or stroke compared to those without. The average person is estimated to ingest several grams of plastic per week via food, water, and air (WWF/University of Newcastle, 2019). No elimination protocol currently exists in conventional medicine.

The paper's central proposed reframing is that microplastics function not merely as chemical toxins but as coherence disruptors, hypothesizing that each particle generates a field signature interfering with the body's electromagnetic organization. This reframing, and the frequency-based intervention approach built on it, is this paper's own hypothesis; the underlying tissue-contamination findings cited above are independently documented. This framework is presented as the human-scale companion to a proposed planetary-scale environmental microplastic remediation concept described elsewhere in the Christos™ library, translating the same proposed coherence-physics principles to the human body.

II. Diagnostic Mapping

Standard blood tests measure dissolved plastic metabolites (phthalates, BPA, PFAS) but cannot locate solid particles in tissue, and CT and MRI cannot resolve particles below roughly 100 microns. The paper proposes a coherence scanning instrument, described as a phased-array piezoelectric spectral analyzer, hypothesized to identify microplastics by their resonant field signatures, on the premise that each plastic polymer type vibrates at a frequency determined by its molecular structure and mass density. The paper proposes a four-step diagnostic sequence: a full-body scan producing a three-dimensional coherence disruption map, spectral analysis matched against a proposed plastic-frequency reference library, baseline blood and urine metabolite testing to chemically cross-confirm findings, and calculation of a baseline coherence index and a proposed total microplastic burden score.

The proposed burden calculation combines a toxicity weighting per plastic type, the amplitude of coherence disruption detected at each location, and estimated tissue penetration depth into a single composite score, with a higher score indicating greater proposed burden and longer proposed elimination timeline. This scoring formula and its associated coefficients are the framework's own proposed mathematical construct, not an independently validated clinical measure.

III. Mobilisation

Microplastics are understood to embed in tissue through hydrophobic interactions, protein corona formation, and mechanical entrapment. The paper proposes that acoustic energy delivered at a plastic particle's resonant frequency could create a selective acoustic radiation force, a phenomenon the paper compares to acoustic tweezers used in microfluidics research, preferentially dislodging particles without damaging surrounding tissue. The paper proposes a dedicated transducer device delivering this energy at intensities described as below established tissue-damage thresholds for therapeutic ultrasound. This mobilisation mechanism, its proposed device, and its proposed treatment sequencing by body region are presented as hypothesis; independent validation has not been established.

IV. Decoherence

The paper proposes that each microplastic particle's electromagnetic field emission actively disrupts the coherent field organization of surrounding tissue, and that the body's inflammatory and fibrotic encapsulation response to a particle impedes its elimination. Building on this, it proposes a phase-conjugation mechanism: broadcasting the phase-inverse of a particle's proposed field emission to drive its net field emission toward zero, described in the paper as rendering the particle electromagnetically undetectable to the body's immune response, allowing natural elimination pathways to clear it without ongoing immune interference. This entire mechanism, the "invisibility effect," and its proposed device are this paper's own hypothesis, not an established immunological or biophysical finding.

V. Coherence Flush and Elimination Pathways

The paper proposes that mobilised, decohered particles still require an exit pathway, and that structured water, described in the paper as carrying a distinctive lattice organization and elevated coherence relative to bulk water, could serve as a directional carrier medium supporting clearance via the body's own established elimination pathways.

5.1 The Eight Proposed Elimination Pathways

The paper organizes proposed elimination support around eight physiological pathways already recognized in human physiology: the lymphatic system, hepatobiliary clearance, intestinal excretion, renal filtration, dermal and sweat clearance, pulmonary mucociliary clearance, circulating blood clearance to the liver and kidneys, and direct mucosal elimination through the gut wall. For each pathway the paper proposes a general category of supportive practice, including manual lymphatic techniques, dietary fiber and probiotic support, hydration, sauna use, and general nutritional cofactor support for gut barrier and hepatic function. Specific supplement compounds, dosages, and session frequencies are not disclosed in this public version, consistent with the standing policy applied across all Christos™ papers: any nutritional or supplement protocol should be developed individually with a qualified physician, not assembled from a published dosage table.

VI. Verification and Maintenance

The paper proposes periodic re-scanning to compare a coherence disruption map against baseline, alongside repeat blood and urine metabolite testing, with an expected transient rise in circulating metabolites during early mobilisation followed by a decline below baseline as elimination proceeds. It proposes calculating an elimination efficiency and a coherence gain against baseline, with protocol intensity or duration proposed to be adjusted if progress falls below an internally defined target. These specific numeric targets are the framework's own proposed treatment benchmarks, not clinically validated endpoints, and are not reproduced at exact value in this public version. The paper also proposes an ongoing quarterly monitoring schedule following the active protocol period.

VII. Cross-Framework Integration

The paper connects this proposed protocol to several companion frameworks described elsewhere in the Christos™ library. It proposes that microplastic burden and a companion coherence-medicine framework's organ-level health measure are bidirectionally linked, microplastic accumulation proposed to lower measured coherence, while lower coherence is proposed to increase tissue retention of particles through altered barrier and clearance function. It proposes that a companion organ-and-mineral frequency mapping framework could provide organ-specific targeting during the flush phase, and connects the protocol to a companion aging framework by proposing microplastic burden as a significant contributor to oxidative and mitochondrial drivers of biological aging, and to a companion organ regeneration framework by proposing that reducing microplastic burden first may improve regenerative outcomes. It further proposes a conceptual bridge to a companion planetary-scale environmental remediation concept, framing the human protocol as the same proposed physics applied at tissue-compatible intensities.

Every specific frequency assignment, session-timing recommendation, and quantified efficacy percentage connecting these frameworks in the source material (for example, specific claims about treatment efficiency improvements or biological age recovery) is the paper's own unvalidated proposal and is not reproduced at exact value in this public version, consistent with the standing policy on dosing and performance claims.

VIII. Prevention Architecture: Material Substitution

Independent of the elimination protocol, the paper proposes a material-substitution strategy addressing several documented sources of ongoing microplastic shedding. Synthetic textile washing is a genuinely documented and substantial microfiber source (Napper & Thompson, 2016, Science of the Total Environment), and tire wear is a genuinely documented major contributor to ocean microplastic pollution (IUCN, 2017). The paper proposes replacing synthetic textiles (polyester, nylon, acrylic, spandex) with natural fiber alternatives (hemp, linen, wool, organic cotton, Tencel), and proposes a redesigned tire construction using natural rubber, biochar, plant-based process oils, and rice husk silica filler in place of synthetic rubber, carbon black, and petroleum oils. It extends similar substitution logic to packaging (glass, stainless steel, bamboo, mushroom-based packaging), paints (lime wash, clay paint), construction materials (clay pipe, bamboo composite, hempcrete), personal care products (ground natural exfoliants, mineral cosmetics), and fishing gear (natural fiber nets and lines).

This material-substitution guidance is general product and lifestyle information rather than a medical protocol, and is presented here in full as public information.

IX. Proposed Devices and Mathematical Framework

The paper proposes five device concepts: a coherence scanning instrument for diagnostic mapping; a sonic mobilisation device; a phase-conjugate frequency generator; a structured-water preparation unit; and an integrated clinical platform combining all four with computer-assisted protocol management, proposed for use by integrative medicine practitioners and wellness clinics rather than home use.

The paper proposes eight extension equations covering burden quantification, mobilisation efficiency, decoherence rate, flush rate, elimination efficiency, coherence recovery, a material-replacement factor, and an overall system-closure condition, stated to build on, but not directly disclose, the framework's permanently protected Core Generator equations. These extension equations, and the empirical constants embedded within them, are the framework's own proposed mathematical constructs and are not independently validated; their exact numeric parameters are not reproduced in this public version.

Estimated production cost for the integrated clinical platform is proposed in the low single-digit-thousands-of-dollars range, with a proposed clinic retail range in the five figures; these are the paper's own cost estimates, not validated pricing, and are the only quantitative figures from this section reproduced here given their economic rather than clinical nature.

X. Clinical Validation and Economics

The paper proposes a Phase 1 proof-of-concept budget in the low six figures covering device prototyping, a small controlled clinical study with biomarker panels, and tissue and coherence monitoring analysis. Three clinical trial designs are proposed, published here in full to support independent evaluation.

10.2 Proposed Regulatory Pathway

The paper proposes classifying its diagnostic scanning and phase-conjugate biofeedback devices as FDA Class I (general wellness, no medical claims), its mobilisation device as FDA Class II pursuing 510(k) substantial equivalence to existing therapeutic ultrasound devices, and its integrated clinical platform as FDA Class II via the 510(k) combination-device pathway, with an estimated 12–24 month timeline for the higher-classification devices. Its water-structuring device is proposed as an unregulated consumer wellness product.

References (Selected)

Amato-Lourenco, L.F., et al. (2021). Presence of airborne microplastics in human lung tissue. THORAX, 76(2), 201–207.
Araujo, C.F., et al. (2023). Identification of microplastics in human brain tissue. Nature Medicine (preprint).
Bassett, C.A.L., Pawluk, R.J., & Pilla, A.A. (1974). Augmentation of bone repair by inductively coupled electromagnetic fields. Science, 184(4136), 575–577.
Engel, G.S., et al. (2007). Evidence for wavelike energy transfer through quantum coherence in photosynthetic systems. Nature, 446(7137), 782–786.
Fadare, O.O., & Okoffo, E.D. (2020). Covid-19 face masks: A potential source of microplastic fibres in the environment. Science of the Total Environment, 737, 140279.
Horvatits, T., et al. (2022). Microplastics detected in cirrhotic liver tissue. eBioMedicine, 75, 103808.
IUCN. (2017). Marine plastic pollution — Issues Brief. International Union for Conservation of Nature.
Leslie, H.A., et al. (2022). Discovery and quantification of plastic particle pollution in human blood. Environment International, 163, 107199.
McCraty, R., & Zayas, M.A. (2014). Cardiac coherence, self-regulation, autonomic stability. Frontiers in Psychology, 5, 1090.
Napper, I.E., & Thompson, R.C. (2016). Release of synthetic microplastic plastic fibres from domestic washing machines. Science of the Total Environment, 568, 1351–1356.
Pollack, G.H. (2013). The Fourth Phase of Water: Beyond Solid, Liquid, and Vapor. Ebner & Sons Publishers.
Ragusa, A., et al. (2021). Plasticenta: First evidence of microplastics in human placenta. Environment International, 146, 106274.
Ragusa, A., et al. (2022). Raman microspectroscopy detection of microplastics in human breastmilk. Polymers, 14(13), 2700.
WWF / University of Newcastle. (2019). No Plastic in Nature: Assessing Plastic Ingestion from Nature to People.
Zhao, Q., et al. (2023). Detection of microplastics in human testicles and their potential effects on male fertility. Science of the Total Environment, 167166.

Intellectual Property & Disclosure Statement

The proposed five-phase elimination protocol, the burden-scoring and treatment-response mathematical framework, the device concepts, the cross-framework integration mapping, the material-substitution prevention architecture, and the proposed clinical trial designs are original work of Joshua Farrior, claimed as intellectual property of Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.

Withheld as trade secrets: the plastic resonant-frequency reference database at exact values; all device engineering specifications; all session durations and treatment scheduling; all supplement compounds, dosages, and combination protocols; and the exact numeric constants within the proposed mathematical framework. These require clinical validation and individualized physician guidance and are not published in any Christos™ paper. The MoR Core Generator equations are permanent trade secrets and are never disclosed in any document. Nothing in this paper constitutes medical, legal, or financial advice.